Health Care · Biological Products, (No Diagnostic Substances)

FDMT 4D Molecular Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 165064883 filings
Russell 2000

FDMT at a glance

4D Molecular Therapeutics, Inc. (FDMT, SEC CIK 1650648) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), 4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.2 million (up 230194.6% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$2.42.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding 4D Molecular Therapeutics, Inc. (FDMT) shares worth $285.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Bizily Scott on October 16, 2026 of 1,635 shares at $12.84 per share.
  • In the last 90 days, FDMT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($2.4M) on Form 4, a net sale of $2.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$85.2M
+230194.6% vs prior year
Insiders · 90 days
0 buys · 7 sells
Net −$2.4M
13F holders
27 funds
$285.4M · +2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $4.1M, up $4.1M YoY, driven by Otsuka clinical development cost sharing and reimbursements
  • Net loss $78.1M vs $56.9M YoY, operating loss $81.2M vs $61.2M
  • Worst-performing area: 4D-150 R&D expenses $43.1M, up $18.1M YoY
  • Cash, equivalents and marketable securities $375.0M, operating cash used $194.8M for nine months
  • Topline data expected in Q2 2027 for 4FRONT-1, with additional funding required and losses expected to continue

Risk Factors

  • Newly triggered debt risk: June 2026 Hercules Loan Agreement, $20.0 million funded against $200.0 million facility
  • Financial risk: $375.0 million in cash, cash equivalents and marketable securities funds planned operations for at least one year
  • Regulatory risk: April 2026 proclamation imposes Section 232 tariffs on imported brand pharmaceuticals, biologics and ingredients beginning July 31, 2026
  • Operational risk: September 2026 launch of 4SIGHT Phase 3 DME trial creates enrollment and execution exposure
  • Competitive risk: Approved therapies from Regeneron, Roche, Vertex and others may hinder physician and payer adoption

AI summary of the FDMT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter 2026 financial results announced for the period ended September 30, 2026
  • Press release includes operational highlights and expected upcoming milestones

Item EX-99.1: Item EX-99.1

  • 4FRONT-1 and 4FRONT-2 randomized 523 and 531 patients, with wet AMD topline data expected Q2 2027 and H2 2027
  • 4SIGHT Phase 3 initiated in DME with 514 patients, testing 4D-150 against aflibercept on vision and injection-burden reduction
Filed Sep 28, 2026Full analysis →

Item 8.01: Other Events

  • 4SIGHT Phase 3 DME trial initiated across multiple sites, enrolling 514 treatment-naïve patients globally
  • Single 4SIGHT trial could support U.S. and European filings, leveraging FDA Regenerative Medicine Advanced Therapy designation
Filed Aug 13, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss widened to $72.9M from $54.7M as R&D rose to $68.3M for Phase 3 wet AMD trials
  • Cash, equivalents and marketable securities declined to $430.6M from $514.0M, with runway projected into H2 2028

Item 2.02: Results of Operations and Financial Condition

  • Second-quarter 2026 financial results for the three months ended June 30, 2026
  • Press release includes operational highlights and expected upcoming milestones

AI summaries of FDMT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for FDMT

Don't miss the next FDMT filing

  • Alerts as it files. A push when FDMT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut FDMT, by share count.
  • Ask anything. An AI agent that reads every FDMT filing and answers with sources.

FDMT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Bizily ScottSellOct 16, 2026$12.84
Bizily ScottMOct 16, 2026$4.14
Bizily ScottMOct 16, 2026-
Kirn DavidSellOct 5, 2026$13.61
Kirn DavidSellOct 5, 2026$12.92
Bizily ScottSellSep 16, 2026$13.65
Bizily ScottMSep 16, 2026-
Bizily ScottMSep 16, 2026$4.14

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$20.7M$37K$85.2M
Operating Income--$187.8M-$159.5M
Net Income-$100.8M-$160.9M-$140.1M
Op. Margin--507678.4%-187.2%
Net Margin-486.6%-434778.4%-164.4%
Balance Sheet
Total Assets-$560.4M$566.7M
Equity-$510.6M$505.7M
ROE--31.5%-27.7%
Per Share
EPS$-2.58$-2.98$-2.42
Cash Flow
Operating CF--$134.6M-$109.1M
CapEx$2.8M$3.8M$536K

Source: XBRL data in 4D Molecular Therapeutics, Inc. (FDMT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate FDMT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
FDMT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$285.4M
Q2 202625$266.4M
Q1 202626$170.4M
Q4 202524$140.0M
Q3 202524$150.0M
Q2 202524$67.8M
Q1 202521$48.2M
Q4 202417$41.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 188 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

FDMT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
4Oct 20, 2026--
4Oct 7, 2026--
8-KSep 28, 2026Analysis-
4Sep 22, 2026--
4Sep 16, 2026--
4Sep 3, 2026--
4Aug 21, 2026--
4Aug 17, 2026--
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Aug 5, 2026--
4Aug 4, 2026--
8-KJul 20, 2026Analysis-
4Jul 14, 2026--
4Jul 2, 2026--
8-KJun 29, 2026Analysis-
4Jun 25, 2026--
4Jun 23, 2026--
8-KJun 22, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--

Related Health Care companies

All Health Care →

FDMT SEC filings: frequently asked questions

Are FDMT insiders buying or selling?

In the last 90 days, 4D Molecular Therapeutics, Inc. (FDMT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $2.4 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold FDMT stock?

As of September 30, 2026, the largest 4D Molecular Therapeutics, Inc. (FDMT) holders among the 13F filers tracked by SignalX were BlackRock ($67.6 million), Goldman Sachs Group ($56.2 million), State Street Corp ($35.3 million), Vanguard Capital Management LLC ($30.6 million), Bank of America Corp ($22.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was FDMT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), 4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.2 million (up 230194.6% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$2.42. The figures come from the XBRL data in the 10-K.

What did FDMT report in its latest 8-K?

4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter 2026 financial results announced for the period ended September 30, 2026.

What are the latest FDMT SEC filings?

4D Molecular Therapeutics, Inc. (FDMT) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 20, 2026.

What is FDMT's SEC CIK number?

4D Molecular Therapeutics, Inc. (FDMT)'s SEC Central Index Key (CIK) is 1650648. EDGAR lists every FDMT filing under that number.

Ask anything about FDMT

The research agent reads FDMT's filings, financials, insider trades and 13F holders, then answers with sources.